Pfizer and BioNTech’s Covid-19 and flu vaccine failed to meet a key goal in a late-stage trial, jeopardising a highly anticipated product that would help the drugmakers to compete in the post-Covid jab market.
辉瑞(Pfizer)和BioNTech的新冠/流感疫苗在后期试验中未能达到一个关键目标，这给这款备受期待的产品带来了风险，该产品将帮助这两家药企在后新冠时代疫苗市场竞争。
您已阅读7%（294字），剩余93%（3687字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。